WithdrawnPhase 4

Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura

Stopped: altered situation in study population; not enough patients meeting enrollment criteria

0Started 2012-09

Plain-language summary

Congenital thrombotic thrombocytopenic purpura (TTP), also called Upshaw-Schulman Syndrome or hereditary or familial TTP is a rare, but severe disease. The purpose of this study is to determine how infusions of plasma to patients with congenital TTP correlate with symptoms and signs of activity of the disease, and to determine why some patients need more frequent infusions of plasma than others to prevent acute attacks of the disease.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Confirmed diagnosis of congenital TTP * On regular prophylactic plasma treatment: \> Once weekly (group 1) or \>1 \<3 times monthly (group 2) * Between 18 and 65 years * Capable of understanding and complying with the protocol Exclusion Criteria: * Pregnancy * Acute bout of TTP requiring daily plasma infusions or -exchange for more than 3 days, within the last 2 weeks before intervention period

What they're measuring

A composite score of clinical and biochemical signs of disease activity

Timeframe: 4 hours and 24 hours after intervention

Trial details

NCT IDNCT01754545

SponsorSt. Olavs Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-11

View on ClinicalTrials.gov More Purpura, Thrombotic Thrombocytopenic trials